OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Orange Book Transparency Act of 2019

Floor Speech

Date: May 8, 2019
Location: Washington, DC
Issues: Health and Health Care Food Processing and Sales

BREAK IN TRANSCRIPT

Mr. GUTHRIE. Mr. Speaker, I rise today in support of H.R. 1503, the Orange Book Transparency Act of 2019.

The Food and Drug Administration's list of approved brand name therapeutic drug products, known as the Orange Book, plays an important role in drug development. H.R. 1503 will ensure the Orange Book continues to be effective and accurate by requiring drug companies to provide up-to-date information on patents that are relevant to each individual drug. It also directs the Government Accountability Office to study the impact of the patents being listed in the Orange Book.

Mr. Speaker, I thank Congresswoman Kelly from Illinois for her commitment to maintaining the value of the Orange Book to drug manufacturers, payers, providers, and patients. I appreciate her willingness to work together in a bipartisan manner, and I urge my colleagues to support H.R. 1503.

BREAK IN TRANSCRIPT


Source
arrow_upward